

Supplementary Table 1. Laboratory and biochemical features of SLE patients and controls

Parameter	Controls (N= 104) M±SD	Patients (N= 113) M±SD	P value
Hemoglobin (g/dl)	13.31 ± 1.33	11.92 ± 4.68	P= 0.001, r=-0.20
WBC (X1000/ μ l)	8.17 ± 1.29	7.89 ± 3.61	NS
ESR (mm/hr)	6.19 ± 1.97	52.94 ± 32.84	P= 0.000, r=0.71
Platelets (x1000/ μ l)	290.43 ± 56.90	235.25 ± 129.84	P= 0.000, r=-0.26
AST (IU/L)	23.77 ± 5.21	23.38 ± 15.18	NS
ALT (IU/L)	20.81 ± 5.02	21.41 ± 15.74	NS
Age years	32.60±9.50	27.31±9.70	NS
Laboratory parameters	M±SE		
Disease duration (years)	7.21±0.53		
Total SLEDAI	9.28 ± 0.73		
C3 titer	65.10±6.60		
C4 titer	32.98±4.46		
Disease activity			
No activity	17 (15.1)		
Mild activity	31 (27.4)		
Moderate activity	22 (19.4)		
High activity	26 (23)		
Sever activity	17 (15.1)		
ACR criteria of SLE	No (%)		
Mucocutaneous manifestation	93 (83%)		
Malar rash	82 (73%)		
Photosensitivity	60 (54%)		
Oral Ulcers	57 (51%)		
Alopecia	34 (30%)		
Serositis	45 (40%)		
Vasculitis	30 (26%)		
Raynauds phenomena	20 (17%)		
Neuropsychiatric disorders	14 (12%)		
Pancytopenia	26 (23%)		
Thrombocytopenia	27 (24%)		
Hemolytic anemia	17 (15%)		
Leucopenia	34 (30%)		
Neutropenia	18 (16%)		
Lymphopenia	35 (31%)		
Arthritis	63 (56%)		
Renal disorders	53 (47%)		
Anti-nuclear Ab	113 (100%)		
Anti-dsDNA Ab	76 (67%)		
Treatment			
No treatment	2 (0.8%)		
Treatment	98 (98.2%)		
Corticosteroid	91 (81%)		
Hydroxychloroquine	95 (84%)		
Cyclophosphamide	54 (48%)		
Azathioprine	71 (63%)		